195 related articles for article (PubMed ID: 6121543)
1. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
[TBL] [Abstract][Full Text] [Related]
3. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
4. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
5. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
6. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap.
Siris SG; Adan F; Cohen M; Mandeli J; Aronson A; Casey E
Am J Psychiatry; 1988 Dec; 145(12):1532-7. PubMed ID: 3057924
[TBL] [Abstract][Full Text] [Related]
7. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics.
Galdi J; Bonato RR
Can J Psychiatry; 1988 Dec; 33(9):816-8. PubMed ID: 2905632
[TBL] [Abstract][Full Text] [Related]
8. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
10. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial.
Siris SG; Bermanzohn PC; Mason SE; Shuwall MA
Arch Gen Psychiatry; 1994 Feb; 51(2):109-15. PubMed ID: 7905256
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial.
Siris SG; Morgan V; Fagerstrom R; Rifkin A; Cooper TB
Arch Gen Psychiatry; 1987 Jun; 44(6):533-9. PubMed ID: 3555386
[TBL] [Abstract][Full Text] [Related]
12. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
13. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate.
Hogarty GE; Munetz MR
J Clin Psychopharmacol; 1984 Feb; 4(1):17-24. PubMed ID: 6141187
[TBL] [Abstract][Full Text] [Related]
15. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
[No Abstract] [Full Text] [Related]
16. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
Chouinard G; Annable L; Kropsky M
J Clin Pharmacol; 1978; 18(2-3):148-54. PubMed ID: 24061
[TBL] [Abstract][Full Text] [Related]
17. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
[TBL] [Abstract][Full Text] [Related]
18. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
McLaren S; Cookson JC; Silverstone T
Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic drugs and depressive syndrome in schizophrenia.
Planansky K; Johnston R
Psychiatr Q; 1980; 52(3):214-21. PubMed ID: 6106954
[TBL] [Abstract][Full Text] [Related]
20. The dysphoric syndrome in schizophrenia and its implications for relapse.
Hirsch SR; Jolley AG
Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
